| Literature DB >> 35151942 |
Wansun Kim1, Soogeun Kim1, Jisang Han2, Tae Gi Kim3, Ayoung Bang1, Hyung Woo Choi4, Gyeong Eun Min5, Jae-Ho Shin6, Sang Woong Moon7, Samjin Choi8.
Abstract
We introduce a label-free surface-enhanced Raman scattering (SERS) biosensing platform equipped with metallic nanostructures that can identify the efficacy of Oxford-AstraZeneca (AZD1222) vaccine in vaccinated individuals using non-invasive tear samples. We confirmed the hypothesis that the tears of people who receive the AZD1222 vaccine may be similar to those of adenovirus epidemic keratoconjunctivitis patients since the Oxford-AstraZeneca vaccine is derived from a replication-deficient ChAdOx1 vector of chimpanzee adenovirus. Additionally, we confirmed the potential of the three markers for estimating the vaccination status via analyzing the signals emanating from antibodies or immunoglobulin G by-product using our label-free, SERS biosensing technique with a high reproducibility (<3% relative standard deviation), femtomole-scale limit of detection (1 × 10-14 M), and high SERS response of >108. Therefore, our label-free SERS biosensing nanoplatforms with long-term storage and robust stability will enable rapid and robust monitoring of the vaccine presence in vaccinated individuals.Entities:
Keywords: Label-free SERS biosensing platform; Near- and far-field properties; Oxford-AstraZeneca vaccine; Stability and robustness; Tear fluids
Mesh:
Substances:
Year: 2022 PMID: 35151942 PMCID: PMC8824302 DOI: 10.1016/j.bios.2022.114079
Source DB: PubMed Journal: Biosens Bioelectron ISSN: 0956-5663 Impact factor: 10.618
Fig. 1(A) Transmission electron microscopy images and (B) UV–Vis absorbance spectra of three nanoparticles. Inset indicates planar color images. Scale bar = 10 nm. (C) UV–Vis reflectance spectra of three nanoplatforms. (D) The 785 nm-excited EMF enhancement map within the corresponding ROIs. Scale bar = 200 nm. (E) Comparative analysis of integral near-field enhancements calculated from the three nanoplatforms depending on three Raman laser excitation sources.
Fig. 2(A–C) SERS spectra of the 10−6 M 2-NAT Raman molecule for the three nanoplatforms depending on the three different Raman laser excitation sources. The asterisk indicates the characteristic peak of 2-NAT Raman probe reporter. Plots of Raman intensities for 2-NAT Raman molecule at 1060 cm−1 peak depending on (D) Raman laser excitation sources and (E) concentrations between 10−14 M and 10−6 M with the 785 nm Raman laser source used in the three nanoplatforms. (F) Stability testing of each nanoplatform over two months. Insets indicate the AuNF geometries immediately (d0) and 60 days (d60) after AuNF fabrication. Scale bar = 10 nm.
Fig. 3Clinical application of the 785 nm Raman laser-excited AuNR nanoplatform to evaluate the effectiveness of the Oxford-AstraZeneca vaccine using human tear samples. (A) SERS spectra of tear samples obtained from four different study groups. The asterisk indicates the significant SERS peaks. (B) SERS spectrum of AZD1222 solution and its Gaussian decomposition. (C) Cluster plot of the four groups with a percentage of variances of PC1 = 47.6%, PC2 = 19.3%, and PC3 = 13.8%. (D) Scree plot of the eigenvalues. (E) PC1–PC3 loading profiles calculated from the principal component analysis algorithm. (F) P-value profiles of a one-way analysis of variance test for SERS spectra of the four groups.